Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Lyles, KW, Colón-Emeric, CS, Magaziner, JS, Adachi, JD, Pieper, CF, Mautalen, C, Hyldstrup, L, Recknor, C, Nordsletten, L, Moore, KA, Lavecchia, C, Zhang, J, Mesenbrink, P, Hodgson, PK, Abrams, K, Orloff, JJ, Horowitz, Z, Eriksen, EF, Boonen, S & NN, NN 2007, 'Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture' New England Journal of Medicine, vol. 357, pp. nihpa40967. https://doi.org/10.1056/NEJMe074941

APA

Lyles, K. W., Colón-Emeric, C. S., Magaziner, J. S., Adachi, J. D., Pieper, C. F., Mautalen, C., ... NN, NN. (2007). Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. New England Journal of Medicine, 357, nihpa40967. https://doi.org/10.1056/NEJMe074941

CBE

Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S, NN NN. 2007. Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. New England Journal of Medicine. 357:nihpa40967. https://doi.org/10.1056/NEJMe074941

MLA

Vancouver

Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al. Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. New England Journal of Medicine. 2007;357:nihpa40967. https://doi.org/10.1056/NEJMe074941

Author

Lyles, Kenneth W ; Colón-Emeric, Cathleen S ; Magaziner, Jay S ; Adachi, Jonathan D ; Pieper, Carl F ; Mautalen, Carlos ; Hyldstrup, Lars ; Recknor, Chris ; Nordsletten, Lars ; Moore, Kathy A ; Lavecchia, Catherine ; Zhang, Jie ; Mesenbrink, Peter ; Hodgson, Patricia K ; Abrams, Ken ; Orloff, John J ; Horowitz, Zebulun ; Eriksen, Erik Fink ; Boonen, Steven ; NN, NN. / Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture. In: New England Journal of Medicine. 2007 ; Vol. 357. pp. nihpa40967.

Bibtex

@article{f1f8a81939f24985b1dfc9325c971650,
title = "Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture",
abstract = "BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture. RESULTS: The rates of any new clinical fracture were 8.6{\%} in the zoledronic acid group and 13.9{\%} in the placebo group, a 35{\%} risk reduction (P = 0.001); the respective rates of a new clinical vertebral fracture were 1.7{\%} and 3.8{\%} (P = 0.02), and the respective rates of new nonvertebral fractures were 7.6{\%} and 10.7{\%} (P = 0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6{\%}) and 141 of 1057 patients in the placebo group (13.3{\%}) died, a reduction of 28{\%} in deaths from any cause in the zoledronic-acid group (P = 0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups. CONCLUSIONS: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and improved survival. (ClinicalTrials.gov number, NCT00046254.).",
author = "Lyles, {Kenneth W} and Col{\'o}n-Emeric, {Cathleen S} and Magaziner, {Jay S} and Adachi, {Jonathan D} and Pieper, {Carl F} and Carlos Mautalen and Lars Hyldstrup and Chris Recknor and Lars Nordsletten and Moore, {Kathy A} and Catherine Lavecchia and Jie Zhang and Peter Mesenbrink and Hodgson, {Patricia K} and Ken Abrams and Orloff, {John J} and Zebulun Horowitz and Eriksen, {Erik Fink} and Steven Boonen and NN NN",
year = "2007",
doi = "10.1056/NEJMe074941",
language = "English",
volume = "357",
pages = "nihpa40967",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society",

}

RIS

TY - JOUR

T1 - Zoledronic Acid in Reducing Clinical Fracture and Mortality after Hip Fracture

AU - Lyles, Kenneth W

AU - Colón-Emeric, Cathleen S

AU - Magaziner, Jay S

AU - Adachi, Jonathan D

AU - Pieper, Carl F

AU - Mautalen, Carlos

AU - Hyldstrup, Lars

AU - Recknor, Chris

AU - Nordsletten, Lars

AU - Moore, Kathy A

AU - Lavecchia, Catherine

AU - Zhang, Jie

AU - Mesenbrink, Peter

AU - Hodgson, Patricia K

AU - Abrams, Ken

AU - Orloff, John J

AU - Horowitz, Zebulun

AU - Eriksen, Erik Fink

AU - Boonen, Steven

AU - NN, NN

PY - 2007

Y1 - 2007

N2 - BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture. RESULTS: The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction (P = 0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P = 0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P = 0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic-acid group (P = 0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups. CONCLUSIONS: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and improved survival. (ClinicalTrials.gov number, NCT00046254.).

AB - BACKGROUND: Mortality is increased after a hip fracture, and strategies that improve outcomes are needed. METHODS: In this randomized, double-blind, placebo-controlled trial, 1065 patients were assigned to receive yearly intravenous zoledronic acid (at a dose of 5 mg), and 1062 patients were assigned to receive placebo. The infusions were first administered within 90 days after surgical repair of a hip fracture. All patients received supplemental vitamin D and calcium. The median follow-up was 1.9 years. The primary end point was a new clinical fracture. RESULTS: The rates of any new clinical fracture were 8.6% in the zoledronic acid group and 13.9% in the placebo group, a 35% risk reduction (P = 0.001); the respective rates of a new clinical vertebral fracture were 1.7% and 3.8% (P = 0.02), and the respective rates of new nonvertebral fractures were 7.6% and 10.7% (P = 0.03). In the safety analysis, 101 of 1054 patients in the zoledronic acid group (9.6%) and 141 of 1057 patients in the placebo group (13.3%) died, a reduction of 28% in deaths from any cause in the zoledronic-acid group (P = 0.01). The most frequent adverse events in patients receiving zoledronic acid were pyrexia, myalgia, and bone and musculoskeletal pain. No cases of osteonecrosis of the jaw were reported, and no adverse effects on the healing of fractures were noted. The rates of renal and cardiovascular adverse events, including atrial fibrillation and stroke, were similar in the two groups. CONCLUSIONS: An annual infusion of zoledronic acid within 90 days after repair of a low-trauma hip fracture was associated with a reduction in the rate of new clinical fractures and improved survival. (ClinicalTrials.gov number, NCT00046254.).

U2 - 10.1056/NEJMe074941

DO - 10.1056/NEJMe074941

M3 - Journal article

VL - 357

SP - nihpa40967

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

ER -

ID: 32571674